GSK highlights Cervarix's cross-protection in Phase III trial
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's vaccine Cervarix has shown more than 90% efficacy in preventing cervical cancer caused by HPV 16 or 18 in young women previously uninfected with these virus types, and has also led to a substantial level of cross-protection against other key cancer-causing HPV types in its pivotal Phase III PATRICIA (HPV 008) trial.
You may also be interested in...
2011 Scrip 100: A new look at cancer chemoprevention
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's Xeplion recommended for EU approval for schizophrenia
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
Pfizer's Xiapex recommended for EU approval for Dupuytren's contracture
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.